Brighton Jones LLC Sells 146 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Brighton Jones LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,848 shares of the medical research company’s stock after selling 146 shares during the period. Brighton Jones LLC’s holdings in Thermo Fisher Scientific were worth $2,042,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its stake in Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after buying an additional 1,008,045 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in Thermo Fisher Scientific by 17,046.7% in the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after purchasing an additional 967,913 shares in the last quarter. Van ECK Associates Corp boosted its stake in Thermo Fisher Scientific by 2,567.5% in the fourth quarter. Van ECK Associates Corp now owns 352,217 shares of the medical research company’s stock worth $186,954,000 after purchasing an additional 339,013 shares in the last quarter. Rathbones Group PLC boosted its stake in Thermo Fisher Scientific by 111.0% in the third quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company’s stock worth $287,996,000 after purchasing an additional 299,338 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Thermo Fisher Scientific by 20.3% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company’s stock worth $863,617,000 after purchasing an additional 287,446 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on TMO shares. HSBC boosted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft boosted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Finally, Raymond James upped their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $607.35.

Thermo Fisher Scientific Stock Down 1.4 %

Shares of Thermo Fisher Scientific stock opened at $568.74 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The company has a market capitalization of $217.09 billion, a P/E ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. The business has a 50-day moving average of $574.58 and a two-hundred day moving average of $531.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. In the last three months, insiders sold 52,277 shares of company stock worth $29,649,264. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.